Pharma Focus Asia

Merck Invests $41 Million in Its Italian Biotech Manufacturing Site of Bari


Merck will invest $41 million in a new production line for the aseptic filling of biotech medicines under isolator at its manufacturing site of Bari, Italy.


The new production is expected to be fully operational in 2022 and it will be equipped with an isolator designed with the latest technologies and with a high level of automation.

The isolator technology represents best practice in aseptic filling of injectable medicines and ensures the highest quality standards and the safety of injectable medicines.

Merck plans to enhance people’s lives around the world by developing a new production line. It will be used for the aseptic filling of Merck’s biotech medicines in the areas of multiple sclerosis, fertility and endocrinology with a capacity of 14 million units per year.

For a fully automated production line under isolator and automated warehouse, Merck has invested $58 Million at the Bari biotech-manufacturing site.

Merck’s biotech manufacturing site in Bari employs 225 people currently.

It is specialized in the fill & finish activities of Merck’s biotech medicines in the areas of multiple sclerosis, fertility and endocrinology for more than 150 countries.

The site is also involved in the manufacturing of some of Merck’s products under development.


Parties InvolvedMerck
Budget$41M USD
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference